行政院國家科學委員會專題研究計畫期中報告 
 
纖維蛋白原及其透明酸修飾物的生醫應用之評估(2/3) 
計畫編號 : NSC 95－2221－E－010－009 
主持人：王盈錦 教授    執行機構：國立陽明大學醫學工程研究所 
 
一、中文摘要 
利用還原胺法偶合sHA及纖維蛋白
原，合成不同接枝比之短鏈透明質酸
(sHA)-纖維蛋白原(fibrinogen)偶合物(SXF, 
S為透明質酸，F為纖維蛋白原，X則代表
接枝比)，並探討此偶合物凝膠的物化性質
與結構分析。 
實驗結果顯示，SXF偶合物之凝膠通
透性 (permeability)、質長比 (mass-length 
ratio)皆隨接枝比的增加而增大，但在接枝
比超過4後有明顯改變。而觀察TEM可知
經sHA改質並不會改變偶合物膠體纖維的
banding距離(22.5nm)，但接枝比6以上之
SXF偶合物(S6.15F與S7.63F)則無法形成
具banding之纖維結構。此結果亦符合CP
值於接枝比4-6處之明顯轉折。 
拉力測試與成膠動態黏度量測的結
果則顯示經短鏈透明質酸改質後之纖維蛋
白其黏著強度、凝膠能力與最終黏度隨著
接枝比增加明顯變小；而膨潤性質測試結
則顯示SXF偶合物凝膠之水含量隨著接枝
比增加而上升，顯示纖維蛋白因短鏈透明
質酸之共價鍵結合而增加其水合性。此
外，由酵素分析結果顯示胰蛋白酶對SXF
偶合物仍具降解能力，但降解速率變慢。 
在本研究中，吾人合成了不同sHA接
枝比的偶合物，此種短鏈透明質酸(sHA)-
纖維蛋白原(fibrinogen)偶合物未來有潛力
應用於不同的生醫用途。 
 
Abstract 
A series of biohybrid molecules 
designated as SXF (S, short chain 
hyaluronic acid, abbreviated as sHA; F, 
fibrinogen; X, graft ratio of S to F in the 
copolymer) were synthesized by coupling 
the reducing end of sHA to fibrinogen.  
The physical properties and structures of the 
SXF gels were evaluated and investigated. 
The permeability and mass-length ratio 
of SXF fibrin gel increased with increasing 
graft ratio, but they changed abruptly at a 
graft ratio of around 4. TEM observation 
revealed that coupling of sHA to fibrinogen 
didn’t affect the formation of banding 
(22.5nm), but this pattern disappeared in the 
fibrin gel network of S6.15F and S7.63F. 
These results were consistent with the 
0.5ml之5mg/ml纖維蛋白原溶液樣品
及標準品加入25μl之25U/ml thrombin(最
終濃度thrombin1.19U/ml，鈣離子20mM)
靜置凝膠24小時。測量波長450nm之OD
值，並經與此濃度下纖維蛋白文獻值
0.0274推算得偶合物之體積分率。 
(2)通透性(permeability)之測量 
0.5ml之5mg/ml纖維蛋白原溶液樣品
及標準品加入25μl之25U/ml thrombin(最
終濃度thrombin1.19U/ml，鈣離子20mM)
於垂直架設之硬性塑膠管中靜置凝膠24小
時。凝膠期間管柱底部包覆一層20 mesh
的 nylon隔板，並在下方以parafilm包覆防
止液體滲漏。凝膠管柱底部浸於pH7.4之
0.02M Tris緩衝溶液，管柱上方接有充滿相
同溶液之塑膠軟管，軟管另ㄧ端以三向閥
上接移液管與另ㄧ液體補充管，如圖3.1。 
待凝膠完成，移除下方parafilm並開
始計時，由移液管中讀取所流失之液體，
測量體積流速。 
(3)結果分析－通透性(permeability)之及
纖維直徑之計算 
將測量之體積流速代入以下公式計
算達西係數 (Darcy constant,Ks)得凝膠塊
之通透性。 
Ks(cm2)=(Q＊L＊η)/(t＊A＊ΔP) ...... (1) 
Q: 流體之體積流速(ml/s) 
L : 凝膠塊之長度(cm) 
η: 流體之黏度(10-2 poise) 
ΔP: 衝體液頂端液面至管柱底端之壓降
(dyne/cm) 
A: 凝膠塊之截面積 
t: 於所給予的壓降下所經歷之時間(s) 
將Ks代入下式得纖維直徑d 
d2=kτψ      (ψ<<1)................... (2) 
τ=Ks: permeability(cm2) 
d: 纖維平均直徑(cm) 
k: 常數值 10 
ψ: 纖維所佔之體積分率 
 
圖3.1：通透性測量儀器架設圖 
 
3.2.質長比(mass length ratio)之測量 
藉由測量質長比可得知經短鏈透明
質酸改質後的纖維蛋白凝膠之纖維大小的
變化，而得到纖維半徑的改變量。可得知
改質後的纖維蛋白凝膠結構上的變化。 
(1)濁度(turbidity)的測量 
將樣品及標準品纖維蛋白原溶液以            
pH 7.4之0.02M Tris-HCl/0.15M NaCl溶液
稀釋至1mg/ml及2mg/ml。各取2毫升置於
3.5.凝膠結構分析-穿透式電子顯微鏡
（TEM）觀察 
利用穿透式電子顯微鏡(TEM)來觀
察SXF偶合物凝膠的微結構，並與未修飾
HA的纖維蛋白(FN)凝膠做比較。將樣品加
入thrombin/CaCl2(最終濃度: thrombin 1.19 
U/ml，鈣離子20mM)後滴於銅網(200 mesh)
上，靜置乾燥30分鐘。經負染、清洗後靜
置乾燥一天。於穿透式電子顯微鏡下觀察。 
 
3.6.凝膠膨潤性質測試 
將5mg/ml純化後樣品及標準品纖維
蛋白原溶液各取1ml，加入25 μl之25 U/ml 
thrombin(最終濃度: thrombin 1.19 U/ml，鈣
離子20mM)凝膠。當水膠達到平衡膨潤之
後，取出水膠並將其置於兩片吸水紙巾間
並在紙巾上方施以兩克重之重量，十秒後
以電子天平秤得濕重(Ws)。再將其置入真
空烘箱中乾燥，秤得乾重(Wd)，計算膨潤
程度q如下式： 
q(％)＝（Ws－Wd）÷ Wd×100…....…(6) 
 
3.7.凝膠機械強度測試 
取兩片24x50mm之蓋玻片，各在一端
邊緣以紙質膠帶固定以防止測試時之滑
動，如圖3.2。 
將濃度9mg/ml之純化樣品及標準品
纖維蛋白原溶液240μl置於一片24x50mm
之 蓋 玻 片 ， 加 入 25 μl 之 100 U/ml 
thrombin，使最後鈣離子濃度為20mM、
thrombin濃度為1.19 units/ml。後於上方蓋
上另一片24x50mm蓋玻片。以1kg重量壓
於其上，靜置10min待其凝膠。凝膠後置
入萬能拉伸機，以5mm/min的拉伸速率負
重從0克開始，紀錄其stress-strain曲線並同
時紀錄黏著強度(Adhesion strength)。 
 
3.8.成膠動態黏度之測量 
配製5mg/ml純化後樣品及標準品纖
維蛋白原溶液，並以12mg/ml之標準品纖
維蛋白原溶液作為對照組。將樣品及標準
品纖維蛋白原溶液各取0.5ml加入25μl之
50U/ml thrombin，並於對照組中加入25 μl 
之BSA，使最後鈣離子濃度為20mM、
thrombin濃度為2.38 U/ml。 
於37℃、轉速250rpm下，每30秒取一
次黏度值，測量成膠之動態黏度。將黏度
對時間作圖，以得成膠黏度變化趨勢。 
 
 
 
圖3.2 凝膠機械強度測試裝置 
nm)、S4.8F(359.89±2.15nm)及S6.6F(399.77
±11.19nm)，而濃度2mg/ml凝膠纖維之直徑
分別為FN(173.94±1.05nm)、S2.2F (232.15±
19.35nm)、S4.8F(385.43±4.97nm)及S6.6F 
(785.98±2.16nm)，由此數據可知，纖維直
徑隨接枝比增加而增加，但與SEM(值如表
4.4)對照，S4.8F及S6.6F之直徑不符合實際
大小，而FN 及S2.2F之纖維其質長比及纖
維半徑皆在合理範圍內。故在符合此方程
式的假設範圍下，質長比隨著接枝比增加
而增加，顯示經短鏈透明質酸改質的纖維
蛋白之單位長度之質量明顯增加，但在接
枝比超4之後因構型的改變因而不符合此
模型下的假設(細長圓柱之構型)，此結果
亦符合CP值於接枝比4-6處之明顯轉折。
由1mg及2mg來比較，也可發現濃度越
高，纖維質長比及直徑均增加，亦符合之
前的文獻結果。 
 
3.可凝結蛋白質（clottable protein，CP）
含量測定 
由表 4.5 可發現，纖維蛋白原的可凝
結蛋白質（clottable protein，CP）約為
97.57%，而與 sHA 物理性混合後的 CP 則
為 97.43%，與纖維蛋白原無顯著差異，說
明與 sHA 的物理性混合並不會改變纖維
蛋白原的凝結能力。而經短鏈透明質酸修
飾過的 SXF 偶合物之測量結果，S1.27F
的 CP 為 94.46%，S4.2F 的 CP 亦有
82.61%，但至接枝比為 6.17 則 CP 值明顯
下降，僅剩 55.54%，而接枝比為 11.2 與
15.98 者 CP 又有回到一平衡值的趨勢，分
別為 50.23%和 45.11%。由圖 4.5 中可知，
CP 值於接枝比 4-6 處，明顯存在一轉折
點，即當纖維蛋白原上的 lysine 被改質數
目超過 6 時，凝結能力即明顯下降，然而
低接枝比(如 1.27)對凝結能力的影響並不
明顯。在此將凝結能力發生劇烈改變處
（82.61% → 55.54%）稱為改質臨界點，
而此點應可提供作為未來實際應用的參
考。 
 
4.穩定性測試 — Trypsin水解 
為了解 sHA 改質後的纖維蛋白原是
否仍具被酵素降解的能力，本研究選用胰
蛋白酶（trypsin）來進行檢測。胰蛋白酶
可水解由 Arg 或 Lys 所形成的胜肽鍵。由
圖 4.6(A)可發現纖維蛋白原經降解後有 3 
個片段產生，與標準品標準曲線(圖 4.7)比
對後，這 3 個片段分別為 Y1（114.1 kD）、
D（77.9 kD）、E（42.1 kD ）。其中，D
（77.9 kD）、E（42.1 kD）片段與文獻中
所提出纖維蛋白原經胰蛋白酶水解的產物
吻合。圖 4.6(A)和表 4.6 中也可看出 SXF 
降解產物與纖維蛋白原明顯不相同。
S1.27F、S4.2F 和 S6.17F 具有 6 個片段，
其中 Y1、D、E 分子量皆較纖維蛋白組來
得高。值得注意的是除了上述的 3 個片段
外，另有其他 3 個片段出現，分別為
109-113 kD（Y2）、102-104 kD（Y3）及
如表4.9所示，SXF偶合物凝膠之水含
量隨著接枝比上升而上升，其值大小依序
為 FN (31.72 ±0.12%) < S2.2F （ 33.45 
±0.09%）< S4.8F（37.80 ±0.35%）< S6.6F
（39.96 ±0.73%），如圖4.10。SXF偶合物
與纖維蛋白標準品比較具顯著差異
(0.001<p<0.05)，顯示纖維蛋白因短鏈透明
質酸之共價鍵結合而增加其水合性。 
 
7.凝膠機械強度測試 
經 由 測 量 不 同 偶 合 物 試 片 之
Adhesion stress如圖4.11，經短鏈透明質酸
改質後之SXF偶合物凝膠其機械強度明顯
變小，黏著強度則隨接枝比增加而減少，
其 值 分 別 為 ： FN (2.21±0.20N)>S2.2F 
(1.62±0.11N) > S4.8F(1.03±0.09N)> S6.6F 
(0.62±0.12N)。而經統計分析，比較不同接
枝比SXF偶合物與改質前纖維蛋白(FN)之
最大粘著強度， P值皆小於0.001，故可知
纖維蛋白經短鏈透明質酸改質前後因結構
上的變化造成機械強度明顯降低。 
 
8.成膠動態黏度之測量 
纖維蛋白原在凝膠(clotting)的過程，
隨著纖維蛋白的凝膠量增多，黏度也隨之
上升，本研究選用濃度5mg/ml的樣品於生
理狀況 (37℃、PH7.4、離子強度0.15)進行
動態黏度之測量，並以BSA取代凝血酶為
對照組，每30秒取一點，測量纖維蛋白及
sHA偶合物凝膠過程之動態黏度，以得知
改質前後纖維蛋白凝膠時間(clotting time)
與最終黏度之變化。結果如圖4.12所示，
凝膠時間隨著接枝比上升而增長，其值依
序為FN(11min)＜S2.2F（14min）＜S4.8F
（19.5min）＜S6.6F（20min），而最終黏
度隨著接枝比上升而降低，其值如表4.10
依序為FN (14.18 cp)＜S2.2F（11.39cp）＜
S4.8F（9.35 cp）＜S6.6F（7.57 cp），故
可知改質後的SXF偶合物凝膠時間有延後
的現象，而其黏度則隨著改質數目增加而
下降。 
 
五、結論 
本研究延續第一年的結果，合成不同
接枝比之HA-fibrinogen偶合物(SXF)，並探
討此偶合物凝膠之物化性質與結構分析。 
通透性與質長比的實驗結果顯示，偶
合物凝膠的孔洞率與單位長度之質量會隨
接枝比增加而提高。TEM觀察的結果亦顯
示可知經sHA改質後並不會改變fibrin纖
維的banding距離(22.5nm)，但與CP值的結
果一致，這些現象在接枝比4-6處便發生改
變，質長比在S4.8F處突降；推算之纖維直
徑在接枝比4以上(S4.8F及S6.6F)之膠體已
與實際大小不符；接枝比6.15以上之偶合
物則無法形成具banding之纖維結構；且CP
值於接枝比4-6處之明顯轉折，故推測於接
枝比4-6處纖維蛋白結構開始改變。另由酵
quantities of protein utilizing the principle 
of protein-dye binding. Analytical 
Biochemistry 72, 248-254. 
10.Mihalyi E., Weinberg R.M., Towne D.W., 
and Friedman M.E. (1976). Proteolytic 
fragmentation of fibrinogen. I. 
Comparison of the fragmentation of 
human and bovine fibrinogen by trypsin or 
plasmin. Biochemistry 15, 5372-5381. 
11.Marcus E. Carr, Jr., and Jan Hermans 
(1978) .Size and Density of Fibrin Fibers 
from Turbidity. Macromolecules 
11(1)46-50 
12.Mosesson M.W. (2003). Fibrinogen 
gamma chain functions. J Thromb 
Haemost 1, 231-238. 
13.Mosesson M.W., Siebenlist K.R., 
DiOrioJ.P., Matsuda M., Hainfeld J.F., and 
Wall J.S. (1995). The role of fibrinogen D 
domain intermolecular association sites in 
the polymerization of fibrin and fibrinogen 
Tokyo II (gamma 275 Arg-->Cys). J Cell 
Sci 96, 1053-1058. 
14.Mian N. (1986). Analysis of cell- 
growth-phase-related variations in 
hyaluronate synthase activity of isolated 
plasma-membrane fractions of cultured 
human skin fibroblasts. Biochemical 
Journal 237, 333-342. 
15.Tomida M., Koyama H., and Ono T. 
(1975). Induction of hyaluronic acid 
synthetase activity in rat fibroblasts by 
medium change of confluent cultures. 
Journal of Cellular Physiology 86, 
121-130. 
16.Weigel P.H., FrostS.J., LeBoeuf R.D., 
and McGary C.T. (1989). Thespecific 
interaction between fibrin(ogen) and 
hyaluronan: possible consequences in 
haemostasis, inflammation and wound 
healing. Ciba Found Symp 143, 248-261. 
 
圖 4.2 纖維蛋白原與 sHA 偶合物凝膠之全波長掃瞄(波長範圍 450nm 至
800nm)，樣品濃度 A)1mg/ml(B)2mg/ml，靜置凝膠 20 小時 
圖 4.3  c/ τλ3 對 λ-2 作圖，濃度 1mg/ml (A)FN(B)S2.2F(C)S4.8F(D)S6.6F 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
450 550 650 750 850
Wavelength
A
bs
or
ba
nc
e
0
0.2
0.4
0.6
0.8
1
450 550 650 750 850
Wavelength(nm)
A
bs
or
ba
nc
e FN
S2.2F
S4.8F
S6.6F
FN+BSA
y = 14.22x + 2E+10
R2 = 0.9832
y = 14.761x + 2E+10
R2 = 0.9922
y = 14.177x + 2E+10
R2 = 0.9923
0.0E+00
5.0E+09
1.0E+10
1.5E+10
2.0E+10
2.5E+10
3.0E+10
0 1E+08 2E+08 3E+08 4E+08 5E+08 6E+08
λ^-2(cm)
C
/(τ
(λ
^3
))
y = 23.267x + 2E+10
R2 = 0.9904
y = 22.771x + 2E+10
R2 = 0.9905
y = 24.49x + 2E+10
R2 = 0.9875
0.0E+00
5.0E+09
1.0E+10
1.5E+10
2.0E+10
2.5E+10
3.0E+10
3.5E+10
0 1E+08 2E+08 3E+08 4E+08 5E+08 6E+08
λ^-2(cm)
C
/(τ
(λ
^3
))
y = 275.15x + 4E+10
R2 = 0.9722
y = 268.67x + 4E+10
R2 = 0.9766
y = 271.36x + 4E+10
R2 = 0.9638
0.0E+00
5.0E+10
1.0E+11
1.5E+11
2.0E+11
0 1E+08 2E+08 3E+08 4E+08 5E+08 6E+08
λ^-2(cm)
C
/(τ
(λ
^3
))
y = 811.43x + 1E+11
R2 = 0.9562y = 803.95x + 9E+10
R2 = 0.9681
y = 811.22x + 1E+11
R2 = 0.976
0.0E+00
1.0E+11
2.0E+11
3.0E+11
4.0E+11
5.0E+11
6.0E+11
0 1E+08 2E+08 3E+08 4E+08 5E+08 6E+08
λ^-2(cm)
C
/(τ
(λ
^3
))
y = 40.689x + 1E+10
R2 = 0.9868
y = 40.851x + 1E+10
R2 = 0.9977
y = 31.556x + 1E+10
R2 = 0.9994
0.0E+00
1.0E+10
2.0E+10
3.0E+10
4.0E+10
0 1E+08 2E+08 3E+08 4E+08 5E+08 6E+08
λ^-2(cm)
C/
(τ
(λ
^3
))
y = 16.093x + 1E+10
R2 = 0.9944
y = 15.747x + 1E+10
R2 = 0.994
y = 15.779x + 1E+10
R2 = 0.9946
0.0E+00
5.0E+09
1.0E+10
1.5E+10
2.0E+10
2.5E+10
0 1E+08 2E+08 3E+08 4E+08 5E+08 6E+08
λ^-2(cm)
C
/(τ
(λ
^3
))
(A) (B) 
(A) (B) 
(C) 
(D) 
(A) 
(B) 
 
表 4.4 纖維蛋白原與 sHA 還原端偶合物之結構特性 
 Fiber diameter (nm) 
FN 172.7 ± 41.5 
FN + S 185.8 ± 36.3 
接枝比 1.27 179.3 ± 20.9 
接枝比 4.20 208.9± 4.5 
接枝比 6.17 247.8 ± 20.6  
 
 
表 4.5 纖維蛋白原與 sHA 偶合物成分分析-可凝結蛋白質含量測定 
 
註：F + S 內含 Fibrinogen 7 mg/ml 和 sHA 1.6 mg/ml，其中 Fibrinogen 及 sHA 莫耳比為 1：20 
圖4.7 酵素降解之電泳標準曲線 
 
表4.6 由SDS-PAGE 電泳所推算之酵素降解片段分子量（0.5% trypsin 25 µl） 
Molecular Weight（kD） 
 
表4.7 由SDS-PAGE 電泳所推算之酵素降解片段分子量（0.5% trypsin 50 µl） 
Molecular Weight（kD） 
 
  
 
    圖4-9 物理性混合不同接枝比含量sHA形成纖維蛋白膠之結構觀察結果 
（A）s2F(mix) （B）s4F(mix) （C）s6F(mix) （D）s8F(mix) 
 
表4.8 實驗組與對照組形成纖維蛋白膠banding距離統計(N=50) 
Fibrin glue 
 copolymer 
banding periodicity (nm) Diameter(nm) 
control 22.5 ± 0.13 47.6 ± 1.58 
控制組 
F 22.5 ± 0.34 49.6 ± 2.3 
s2.34F 22.2 ± 0.61 52 ± 2.41 
s4.15F 22.0 ± 0.38 54.7 ± 3.89 
s6.51F - 26.2 ± 14.8 
實驗組 
s7.63F - 18.6 ± 10.2 
s2F(mix) 22.5 ± 0.51 48.3 ± 2.1 
s4F(mix) 22.4 ± 0.64 47.5 ± 1.3 
s6F(mix) 22.5 ± 0.12 48.9 ± 3.7 
對照組 
s8F(mix) 22.5 ± 0.29 49.6 ± 1.7 
註：banding periodicity 與 diameter 所量測的 fiber 數目共 50 條，每一條量 20 處。 
(A) (B) 
(C) (D) 
圖4.11 纖維蛋白原與sHA偶合物試片的最大黏著強度值之比較 
 
 
圖4.12 纖維蛋白原與sHA偶合物成膠動態黏度變化圖 
 
 
表4.10 纖維蛋白原與sHA偶合物之凝膠時間及黏度測試 
二、與會心得 
 
參加國際會議不但可以觀摩各國的研究成果，拓展視野，廠商展示區也可
以讓我們了解目前業界的進展，並獲得可幫助研究的最新原料與儀器資訊。建議
多鼓勵參與國際會議，並視不同物價水平區域提高補助，以激勵、提升研究水平。  
Introduction 
Bone marrow mesenchymal stem cells (MSCs) (1) from human bone marrow have 
been found to possess the capacity for self-renewal and the plural-potential to 
differentiate into osteocytic, chondrocytic, and adipocytic lineages (2-3).  Thus, 
MSCs could substitute for chondrocytes as a source of cell in therapeutic application 
for engineering the repair of osteochondral defects.  MSCs with a homogeneous 
population could be obtained by using a plastic culture dish comprising a plate with 
3-microm pores was used to sieve out the MSCs from bone marrow and expanded in 
vitro (4).  These isolated MSCs have the potential of differentiation into 
chondrogenic cells if induced by TGF-β.     
  Numerous materials have been proposed, and are being developed as scaffolds for 
use in cartilage repair.  An ideal biomaterial should promote stem cell the synthesis 
of collagen type II and proteoglycans to provide an environment supportive of 
chondrogenesis.  Hyaluronic acid (HA), a major component of articular cartilage, 
has been tested for its ability to enhance the repair of osteochondral defects (5-6).  
HA plays an important role of morphogenesis by regulating cell division and 
migration within the extracellular matrix (ECM).  On the other hand, fibrin gel could 
be used as a cell carrier other than merely serving as a tissue sealant with some 
negative effects reported (7-8).  In this study, we have constructed the matrices of 
fibrin combined with HA and evaluated their performances as the cell carrier of MSCs 
used for the scaffold for cartilage tissue engineering.  
 
Methods 
Isolation and chondrogenesis of bone marrow mesenchymal cells  
  Human MSCs were isolated according to the method as previously described (4). 
The isolated cells were either cultured in a monolayer mode or as pellet.  For 
the EDC as the crosslinking agent.  MSCs were mixed with the HA-collagen fibrils 
and chondropheres were prpeared similar to that of gibrin gel. 
Histochemical staining 
The medium was removed from various culture systems, and cells were washed 
twice with PBS. Cells were fixed in 3.7% paraformaldehyde overnight at 4 ℃ for 
frozen sections. Sections of 6 mm thickness were cut through the center of the 
constructs and were stained with haematoxylin-eosin (H&E) and Acridine orange 
fluorescence stained (AO) to show chondrogenic differentiation. 
Immunohistochemistry staining  
The cells-containing specimens were washed twice with PBS, and fixed in 3.7% 
paraformaldehyde overnight at 4 ℃.  For immunohistochemical analysis, specimens 
were stained with human type I, II and X collagens to detect the chondrogenic 
differentiation of the treated cells. 
Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis 
   To ensure that all cells within the polymers were subjected to RT-PCR analysis, 
the upper half of the polymers, including the coated cell layers, were removed with a 
scalpel and total cellular RNA was isolated from the polymers or the control cell 
pellets using Trizol reagent (Gibco BRL) and extracted with chloroform.  Briefly, 
the polymers plus the cell layer were transferred to a 1.5-mL microcentrifuge tube 
and dissociated in 0.5 mL of Trizol using a pellet pestle (Kontes).  RNA was 
extracted with chloroform and precipitated with isopropanol, and the resulting pellet 
was stored at -80°C in 75% ethanol.  Before RT-PCR analysis, the RNA pellet was 
dried, dissolved in nuclease-free water, and the RNA concentration determined by 
CTTCAGCACCTGTCTCACCA 
AGN  
Sense: 
GAGGAGGGCTGGAACAAGTACC 
Antisense: 
GGAGGTGGTAATTGCAGGGAACA
 
Scanning electron microscopy 
After harvested, the cell–polymer constructs were rinsed three times in 0.1 M 
cacodylate buffer (pH 7.2) and fixed overnight in cacodylate buffered 2.5% 
glutaraldehyde at 4°C.  The specimens were postfixed in 1% OsO4 for 1.5 h, 
dehydrated through a graded series of ethanol, dried in a Polaron critical point drier 
(VG Microtech), mounted onto aluminum stubs, sputter coated with gold, and viewed 
under a scanning electron microscope. 
 
Results  
Chondroinduction of size-sieved bone marrow stem cells in monolayer culture 
The cells grown in monolayer culture were evaluated to determine the effect of 
recombinant human TGF-ß1（10 ng/ml） in chemically defined medium on human 
mesenchymal stem cell monolayer cultures.  As shown in Figure 1, cells had 
fibroblast-like morphology and had reached confluence with a consistent and 
homogeneous morphology on day 1.  On day 17, the cells acquired a more polygonal 
shape and had grown into multilayered form.  On day 28, the cells became more 
spindle-shaped and detached from the culture dishes to accumulate and pile up.  On 
day 35, the cells showed well-established structure as pile-ups and started floating 
around on day40.  By day 51, the cells had floated more and grown sparser.   
     
  (A)                    (B)                 (C)  
Figure 3：FITC-conjugated mmunohistochemical analysis of frozen sections of cell 
aggregates cultured at 14th day.  The sections were immunostained with antibodies 
reactive on epitope within (A) Type II Collagen, (B) Type I Collagen and (C) Type X 
Collagen.  Cells were grown in suspension culture with 10.0 ng/ml TGFβ1 at 14th 
day after seeding. 
 
Total RNA was analyzed by RT-PCR for mRNA expression.  The expression of 
type X (703bp), type I (451 bp), type II (339 bp) collagens and aggrecan (360bp) were 
examined in cell aggregates.  The expression of β-actin (515 bp) was also examined 
as an internal control.  Non-treated (N) cell aggregate was used as a negative control 
(Figure 4).  Despite using equal volumes of RT products, the expression of the 
β-actin was somewhat variable.  However, specific PCR products for cartilage (type 
II, type I, type X collagens and aggrecan) were expressed in the 15th-day cell 
aggregates.  The findings supported the positive results obtained for type I and type 
X collagens in the immunohistochemistry study.  Moreover, it supports the 
expression of type II collagen that was unable to be detected in the 
immunohistochemistry study.  
 
under 3500X magnification (Figure.5C).  As shown in Figure 5D, fine fibrils were 
found in the matrix under SEM of 7000X magnification. 
 
A：day5（500X）  B：day14（500X） 
  
C：day5（3500X）  D：day14（7000X） 
Figure 5：Representative scanning electronic microscope micrographs - cells grown in 
fibrin gel polymer materials with 10.0 ng/ml TGFβ1 at 5th and 14th days after 
seeding. 
 
The cells entrapped in the fibrin gel could be seen clearly after stained with 
fluorescent Acridine orange agent for DNA and RNA.  As shown in Figure 6, green 
light stands for the presence of DNA, while orange light for RNA.   
 
 
 
Figure 6： Photograph of DNA and RNA stain with AO.  Cells grown in fibrin gel 
with 10.0 ng/ml TGF-β1 at 14th days after seeding. 
 
gel matrix and HA/fibrin gel matrix for 14 days after transfected.  And the 
expressions of type II collagen and aggrecan were detected by quantitative PCR.  
MSCs cultured in fibrin matrix expressed almost 2-fold higher amounts of type II 
collagen than those grown in a monolayer.  In HA/fibrin gel culture system, type II 
collagen mRNA expression was 1.5-fold higher compared to cultured in fibrin system.  
In addition, the aggrecan mRNA expression in MSCs recovered from HA/fibrin gel 
system was 1.2-fold higher than the expression level of cells in the fibrin gel system.  
These results indicate that the presence of HA in fibrin glue is advantageous for the 
chondorgenesis of MSCs.  
 
Discussion  
Mesenchymal stem cells (MSCs) were first isolated by Friedenstein at al (1976) 
based on their adherence to culture devices.  In previous reports, MSC have been 
found to be difficult to isolate and are usually contaiminated by hematopoietic 
precursors.  This study utilizes a unique method developed by Hung.  In monolayer 
culture system, the chondrocytic cells (round cells) appeared after 28 days of seeding. 
Studies with isolated chondrocytes have shown the importance of both cell-cell and 
cell-matrix associations for their differentiation and phenotypic expression [9].  
Proteoglycan aggregates are formed in the matrix, binding at their N-termini to a 
chain of hyaluronan, the binding being stabilized by a separate globular link protein 
[10].  Matrix molecules are known to influence the growth characteristics of cells 
and to modulate various aspects of cell behavior, including adhesion and spreading 
[11].  Several studies have used 3D culture systems as models for cartilage tissue.  
For example, chick limb chondrogenesis was evaluated under high-density micromass 
culture conditions, which enhanced 3D condensation of the cells [12].  Maintenance 
Although HA is known to be beneficial to cell chondrogenesis, the use of HA alone 
either in solution or as gel state faces the problem of early loss of matrix before 
chondrogenesis takes place due to the diffusion and biodegradation of HA.  By 
forming the hybrid of fibrin and HA, the HA loss can be reduced.  In addition, the 
interconnected pore structure formed in the gel system provides an excellent 3-D 
environment for cell growth and chondrogenesis.  Analysis of the gene expression of 
the ECM molecules confirmed the benefits of the composite with added HA in the 
expression and maintenance of phenotypic stability.  The present study suggests that 
fibrin/HA composite may serve as a dependable cell delivery vehicle as well as a 
structural basis for tissue-engineered cartilage. 
 
Conclusion 
    To conclude, the human size-sieved mesenchymal stem cells with relative 
homogeneity and capacity for renewal may be one of the ideal stem cells for 
therapeutic or diagnostic purposes.  In combination with HA/fibrin gel, a biohybrid 
construct of synthetic cartilage could be formed and serve as a potential delivery 
vehicle of tissue-engineered cartilage repair. 
Acknowledgement 
This study was supported by a grant (NSC 95-2221-E010-009) from National Science 
Council from Taiwan, ROC. 
 
References 
1.Friedenstein, A.J., Piatetzky-Shapiro, I.I.,      and Petrakova, K.V. Osteogenesis 
in transplants of bone marrow cells. J. Embryol. Exp. Morphol. 16(1966), 381-90. 
